vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and BayFirst Financial Corp. (BAFN). Click either name above to swap in a different company.

Aquestive Therapeutics, Inc. is the larger business by last-quarter revenue ($13.0M vs $10.3M, roughly 1.3× BayFirst Financial Corp.). BayFirst Financial Corp. runs the higher net margin — -55.0% vs -244.8%, a 189.8% gap on every dollar of revenue. Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs -29.6%).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

AQST vs BAFN — Head-to-Head

Bigger by revenue
AQST
AQST
1.3× larger
AQST
$13.0M
$10.3M
BAFN
Higher net margin
BAFN
BAFN
189.8% more per $
BAFN
-55.0%
-244.8%
AQST
Faster 2-yr revenue CAGR
AQST
AQST
Annualised
AQST
3.9%
-29.6%
BAFN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AQST
AQST
BAFN
BAFN
Revenue
$13.0M
$10.3M
Net Profit
$-31.9M
$-5.7M
Gross Margin
55.2%
Operating Margin
-221.6%
Net Margin
-244.8%
-55.0%
Revenue YoY
9.7%
Net Profit YoY
-86.8%
-130.6%
EPS (diluted)
$-0.26
$-1.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
BAFN
BAFN
Q1 26
$10.3M
Q4 25
$13.0M
$11.2M
Q3 25
$12.8M
$10.2M
Q2 25
$10.0M
$23.1M
Q1 25
$8.7M
$19.8M
Q4 24
$11.9M
$32.9M
Q3 24
$13.5M
$21.7M
Q2 24
$20.1M
$20.8M
Net Profit
AQST
AQST
BAFN
BAFN
Q1 26
$-5.7M
Q4 25
$-31.9M
$-2.5M
Q3 25
$-15.4M
$-18.9M
Q2 25
$-13.5M
$-1.2M
Q1 25
$-22.9M
$-335.0K
Q4 24
$-17.1M
$9.8M
Q3 24
$-11.5M
$1.1M
Q2 24
$-2.7M
$866.0K
Gross Margin
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
Q1 25
58.1%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
Operating Margin
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
-221.6%
-25.3%
Q3 25
-89.6%
-253.0%
Q2 25
-113.6%
-7.1%
Q1 25
-222.1%
-2.3%
Q4 24
-114.4%
Q3 24
-61.2%
7.1%
Q2 24
0.3%
5.9%
Net Margin
AQST
AQST
BAFN
BAFN
Q1 26
-55.0%
Q4 25
-244.8%
-22.1%
Q3 25
-120.6%
-184.7%
Q2 25
-135.4%
-5.3%
Q1 25
-263.0%
-1.7%
Q4 24
-143.7%
91.8%
Q3 24
-85.0%
5.2%
Q2 24
-13.7%
4.2%
EPS (diluted)
AQST
AQST
BAFN
BAFN
Q1 26
$-1.48
Q4 25
$-0.26
$-0.71
Q3 25
$-0.14
$-4.66
Q2 25
$-0.14
$-0.39
Q1 25
$-0.24
$-0.17
Q4 24
$-0.18
$2.21
Q3 24
$-0.13
$0.18
Q2 24
$-0.03
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
BAFN
BAFN
Cash + ST InvestmentsLiquidity on hand
$134.5M
Total DebtLower is stronger
$27.5M
Stockholders' EquityBook value
$-33.7M
$81.9M
Total Assets
$160.4M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
BAFN
BAFN
Q1 26
$134.5M
Q4 25
$207.0M
Q3 25
$129.1M
$118.5M
Q2 25
$60.5M
$77.3M
Q1 25
$68.7M
$63.2M
Q4 24
$71.5M
$77.8M
Q3 24
$77.9M
$64.4M
Q2 24
$89.9M
$60.8M
Total Debt
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
$27.5M
Q3 25
$45.0M
Q2 25
$45.0M
Q1 25
$45.0M
Q4 24
$32.5M
Q3 24
$45.0M
Q2 24
$45.0M
Stockholders' Equity
AQST
AQST
BAFN
BAFN
Q1 26
$81.9M
Q4 25
$-33.7M
$87.6M
Q3 25
$-4.1M
$89.7M
Q2 25
$-72.6M
$108.2M
Q1 25
$-60.9M
$110.1M
Q4 24
$-60.2M
$110.9M
Q3 24
$-45.4M
$102.3M
Q2 24
$-35.5M
$101.0M
Total Assets
AQST
AQST
BAFN
BAFN
Q1 26
$1.2B
Q4 25
$160.4M
$1.3B
Q3 25
$163.6M
$1.3B
Q2 25
$93.7M
$1.3B
Q1 25
$102.2M
$1.3B
Q4 24
$101.4M
$1.3B
Q3 24
$110.0M
$1.2B
Q2 24
$117.6M
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
BAFN
BAFN
Operating Cash FlowLast quarter
$-8.5M
Free Cash FlowOCF − Capex
$-8.6M
FCF MarginFCF / Revenue
-65.7%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-53.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
$-8.5M
$285.3M
Q3 25
$-12.6M
$47.3M
Q2 25
$-7.9M
$63.3M
Q1 25
$-23.4M
$74.2M
Q4 24
$-6.5M
$390.5M
Q3 24
$-11.9M
$90.8M
Q2 24
$-7.0M
$78.8M
Free Cash Flow
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
$-8.6M
$285.0M
Q3 25
$-12.9M
$47.3M
Q2 25
$-8.0M
$63.1M
Q1 25
$-23.5M
$74.1M
Q4 24
$-6.5M
$388.8M
Q3 24
$-12.0M
$90.5M
Q2 24
$-7.0M
$78.4M
FCF Margin
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
-65.7%
2554.2%
Q3 25
-100.6%
462.2%
Q2 25
-80.2%
272.7%
Q1 25
-269.9%
375.1%
Q4 24
-54.8%
1180.9%
Q3 24
-88.3%
416.5%
Q2 24
-35.0%
376.1%
Capex Intensity
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
0.7%
2.7%
Q3 25
1.8%
0.1%
Q2 25
1.1%
0.8%
Q1 25
1.5%
0.4%
Q4 24
0.1%
5.1%
Q3 24
0.6%
1.5%
Q2 24
0.2%
1.9%
Cash Conversion
AQST
AQST
BAFN
BAFN
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
39.95×
Q3 24
79.85×
Q2 24
90.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AQST
AQST

Segment breakdown not available.

BAFN
BAFN

Net Interest Income$9.4M91%
Noninterest Income$884.0K9%

Related Comparisons